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Abstract.  Using mAb technology (Wayner,  E. A., 
W. G.  Carter, R.  Piotrowicz, and T. J.  Kunicki.  1988. 
J.  Cell Biol.  107:1881-1891), we have identified a new 
fibronectin receptor that is identical to the integrin 
receptor a4B1.  mAbs P3E3, P4C2, and P4G9 recog- 
nized epitopes on the tx4 subunit and completely in- 
hibited the adhesion of peripheral blood and cultured 
T lymphocytes to a 38-kD tryptic fragment of plasma 
fibronectin containing the carboxy-terminal Heparin II 
domain and part of the type III connecting segment 
(IIICS). The ligand in IrlCS for ot4B1 was the CS-1 
region previously defined as an adhesion site for mela- 
noma cells. The functionally defined mAbs to or4 par- 
tially inhibited T  lymphocyte adhesion to intact plasma 
fibronectin and had no effect on their attachment to an 
80-kD tryptic fragment containing the RGD (arg-gly- 
asp) adhesion sequence, mAbs (P1D6 and P1F8) to the 
previously described fibronectin receptor, ot5B1, com- 
pletely inhibited T lymphocyte adhesion to the 80-kD 
fragment but had no effect on their attachment to the 
38-kD fragment or to CS-1. Both ot4/~l and ot5/31 
localized to focal adhesions when fibroblasts that ex- 
press these receptors were grown on fibronectin-coated 
surfaces. These findings demonstrated a specific inter- 
action of both receptors with fibronectin at focal con- 
tacts. 
In conclusion, these findings show clearly that cul- 
tured T  lymphocytes use two independent receptors 
during attachment to fibronectin and that (a) ~x5~l is 
the receptor for the RGD containing cell adhesion do- 
main, and (b) ot4~l  is the receptor for a carboxy- 
terminal cell adhesion region containing the Heparin II 
and IIICS domains. Furthermore, these data also show 
that T lymphocytes express a clear preference for a re- 
gion of molecular heterogeneity in IIICS (CS-1) gener- 
ated by alternative splicing of fibronectin pre-mRNA 
and that o~4~1 is the receptor for this adhesion site. 
W 
'E and others (reviewed by Hynes, 1987; Hemler, 
1988) have described specific cell surface receptors 
for the extracellular matrix (ECM) l components 
collagen, fibronectin, and laminin.  The functions of the ex- 
tracellular matrix receptors (ECMRs I, II, and VI) we de- 
scribed were defined by affinity chromatography (Wayner 
and Carter, 1987; Staatz et al., 1989) and by preparing mAbs 
that specifically  inhibited  the interaction  of cells with pu- 
rified ligands (Wayner and Carter,  1987) or ECM (Wayner 
et al.,  1988). The ECMRs  are members of the integrin 
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1. Abbreviations used in this paper: BLCL, B lymphocyte cell line; CTL, 
cytotoxic T lymphocytes;  ECM, extracellular matrix; ECMR, extracellular 
matrix receptor; HBSA, heat-denatured BSA; LAK, lymphokine-activated 
killer cells; LGL, large granular lymphocyte  leukemia; RD, human rhab- 
domyosarcoma  cells; IIICS,  type III connecting segment region. 
(Hynes, 1987) family of cell adhesion molecules and possess 
unique ot  subunits  complexed  to the  integrin  /~1  subunit 
(Wayner and Carter,  1987; Wayner et al., 1988). ECMR VI 
is identical to the prototype fibronectin receptor (Pytela et 
al., 1985), c~5/31, platelet glycoprotein (gp) Ic/IIa, and VLA 
5; ECMR II is identical to c~2~1, platelet gp Ia/IIa and VLA 
2 (Hemler et al., 1987b); and ECMR I is identical to ot3/~l 
and  VLA 3  (Kunicki  et al.,  1988; Takada et al.,  1988; 
Wayner et al., 1988). Monoclonal antibodies to ot2/31, oL3/31 
and c~5~/1 (P1H5, P1D6, and P1B5) inhibit fibroblast or plate- 
let adhesion to collagen, fibronectin and laminin-coated sur- 
faces (Kunicki et al.,  1988; Wayner et al.,  1988). 
The ffl integrins are differentially expressed in cultured 
cells and tissue, and demonstrate clear differences in activa- 
tion dependent expression. For example, expression of ct5/~l 
in hematopoietic cells is restricted to subpopulations of thy- 
mocytes and peripheral blood lymphocytes, monocytes, acute 
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migrating hemopoietic precursor cells, and some cultured T, 
B,  or  erythroleukemia  cell  lines  (Bernardi  et  al.,  1987; 
Cardarelli  et al., 1988; Garcia-Pardo et al., 1989; Giancotti 
et al., 1986; Liao et al., 1987; Savagner et al., 1986; Wayner 
et al.,  1988). 
In experiments  designed to examine the function  of oL5~l 
in lymphocytes,  we observed that resting  periperhal blood 
and cultured T lymphocytes (Molt 4 or Jurkat) expressed an 
affinity for fibronectin  independent  of the prototype fibro- 
nectin receptor, o~5/~1. Although these cells attached to fibro- 
nectin-coated  surfaces (unpublished),  they expressed low or 
undetectable  levels of ct5/31 recognized by our functionally 
defined mAb, P1D6 (Wayner et al.,  1988). Furthermore, T 
lymphocyte adhesion  to fibronectin  could only be partially 
inhibited by P1D6- or RGD-containing  peptides,  suggesting 
the  involvement  of other  receptors  for fibronectin  in  the 
adhesion  process. Alternatively,  adhesion  of other cells to 
fibronectin such as malignant or transformed  fibroblasts and 
activated T lymphocytes (lymphokine-activated  killer [LAK] 
cells) could be completely inhibited by P1D6. This suggested 
that resting peripheral  blood T lymphocytes and cultured T 
cell leukemias express multiple  independent  and functional 
fibronectin  receptors. 
Therefore,  we identified an alternative fibronectin receptor 
by preparing  mAbs that specifically  inhibited  the adhesion 
of T lymphocytes to fibronectin.  This receptor was identical 
to the integrin receptor ot4~l and mediated the attachment of 
peripheral  blood lymphocytes, cultured T cell lines, and RD 
cells to plasma fibronectin.  Furthermore, as we have shown 
(Garcia-Pardo,  A., and O. C. Ferreira, manuscript submitted 
for publication)  T lymphocytes expressed a clear preference 
for a 38-kD tryptic fragment of plasma fibronectin  (Garcia- 
Pardo et al.,  1987) containing  the Heparin II domain and 
67 amino acid residues of the type III connecting  segment 
(IIICS) spanning the CS-1, CS-2, and CS-3 regions defined 
by Humphries et al.  (1986, 1987).  T lymphocytes attached 
only to CS-I  and mAbs to c~4/31 (P3E3, P4C2, P4G9) com- 
pletely inhibited T lymphocyte adhesion  to the 38-kD frag- 
ment and to CS-1. T lymphocytes also attached  (with much 
lower affinity) to a site present in the heparin  II domain and 
mAbs to a4~l also inhibited this interaction.  The function- 
ally  defined  mAbs to oA/~l did not inhibit  T  lymphocyte 
adhesion to an 80-kD tryptic fragment of plasma fibronectin 
containing  the RGD sequence, whereas antibodies to a5/31 
completely inhibited  this interaction.  These data show that 
T lymphocytes bear at least two receptors for fibronectin and 
clearly identify tx4/~l as the receptor for adhesion  site(s) lo- 
cated in the carboxy-terminal  region of plasma fibronectin. 
Materials and Methods 
Materials 
PMSE N-ethylmaleimide,  leupeptin, diisopropyl  fluorophosphate,  2-mer- 
captoethanol, BSA, Triton X-100, Protein A-agarose, soybean trypsin inhib- 
itor, and V8 protease (from Staphylococcus  aureus, strain VS, protease type 
XVII) were purchased from Sigma Chemical Co.  (St.  Louis,  MO).  Lac- 
toperoxidase  and glucose oxidase  were  from Calbiochem-Behring Corp. 
(La Jolla, CA).  TPCK-trypsin was  from Cooper Biomedicais  (Malvern, 
PA).Fluorescein-conjugated  goat anti-mouse IgG and IgM (heavy [H] and 
light [L] chains) or rhodamine-conjugated  goat anti-rabbit IgG and IgM (H 
and L chains) were  obtained from Tago, Inc.  (Burlingame,  CA).  R-phy- 
coerythrin-conjugated strepavidin was  from Biomeda (Foster  City,  CA). 
Rabbit anti-mouse IgG (H and L) antiserum was obtained from Cappel Lab- 
oratories (Malvern, PA). [51Cr] Sodium chromate was from New England 
Nuclear (Boston, MA). '2sI was from Amersham Corp.  (Arlington Heights, 
IL). Human recombinant IL 2 was a generous gift from Dr. D. Urdal (Im- 
munex Corp., Seattle, WA). Laminin was purchased from Collaborative Re- 
search, Inc.  (Bedford,  MA) and purified plasma fibronectin and collagen 
types I and III were prepared as previously described (Wayner and Carter, 
1987; Wayner et al.,  1988). 
Cells and Cell Culture 
RD (human rhabdomyosarcoma)  and HTI080 (human fibrosarcoma)  cells 
were obtained from the American Type  Culture Collection (Rockville, 
MD).  PBMC, platelet,  and granulocyte  populations from normal human 
donors were prepared as described (Kunicld et al.,  1988; Wayner et al., 
1988). Peripheral blood cells from patients with acute lymphocytic,  large 
granular lymphocyte (LGL), or myelogenous leukemia were obtained from 
Dr. I. Bernstein and Dr. T. Longhran (Fred Hutchinson Cancer Research 
Center). Human LAK cells (500 U/ml IL 2) and the monoclonal  HLA B'/- 
specific human cytotoxic T lymphocyte  (CTL) cell line, CIC4, were pre- 
pared according to standard protocols (Grimm et al., 1982; Glasebrook and 
Fitch, 1980; Brooks,  1983; Wayner and Brooks,  1984; Wayner and Brooks, 
1985). The EBV-transformed B lymphocyte cell line (BLCL) ST-I, was de- 
rived from the donor spleen used in the production of the CIC4 CTL line. 
All other cell lines and cell culture conditions were as previously described 
(Wayner and Carter,  1987; Wayner et al.,  1988). 
Antibodies 
A rabbit polycional antibody, AB33, prepared against the cytoplasmic  do- 
main of the fibronectin receptor,  ~5/~1, (Roman et al.,  1988) was used to 
detect a5/31 in focal adhesions, mAbs ALAS, against the common integrin 
(Hynes, 1987) E1 subunit of the VLA family of receptors  (Hemler,  1988) 
and B5-GI0 to the VLA 4 ~  subunit (Hemler et al.,  1987) were obtained 
from Dr.  Martin Hemler (Dana-Farbar Cancer Institute,  Boston, MA). 
mAbs to the integrin receptors ,3/31 (PIB5), c~2/31 (PIH5), and ~5/~1 (PID6) 
have been described. PIH5 and PID6 inhibit fibroblast and platelet adhesion 
to collagen  and fibronectin-coated  substrates,  respectively  (Wayner  and 
Carter,  1987; Kunicki et ai.,  1988; Wayner et al.,  1988). 
mAbs to lymphocyte adhesion receptors  were produced by the methods 
of Oi and Herzenberg (1980) and Taggart and Samloff (1983) as described 
(Wayner and Carter,  1987; Wayner et al.,  1988).  Spleens from RBF/Dn 
mice immunized  with 100 t~l of packed T lymphocytes  were removed and 
fused with NS-I/FOX-NY  myeloma cells.  Viable heterokaryons  were se- 
lected  in  RPMI  1640  medium  supplemented  with  adenine/aminopte- 
rin/thymidine (Taggart and Samloff,  1983).  Hybridomas producing anti- 
body directed to lymphocyte adhesion receptors  were screened by specific 
inhibition  of lymphocyte adhesion to fibronectin-coated  surfaces and cloned 
by limiting dilution. 
Inhibition of Cell Adhesion to Intact Fibronectin and 
Fibronectin Fragments 
Antibodies that would alter cell adhesion to purified  plasma fibronectin, 
tryptic fragments and CS peptides  were identified as previously  described 
(Wayner  and Carter,  1987).  Briefly, 48-well  virgin styrene plates were 
coated  with 5 #g/ml human plasma fibronectin. The plates were blocked 
with PBS supplemented with  10 mg/ml heat-denatured BSA (HBSA).  T 
lymphocyte or HT1080 cells were labeled with Na251CrO4 (50 ~Ci/mi for 
2-4 h) and washed,  and 5  ×  104 HTI080 or cultured T cells or 5  ×  105 
PBL/well were incubated with hybridoma culture supernatants  (1:2 dilution 
in PBS supplemented with 1 mg/ml HBSA) or control myeloma cell culture 
supernatant for 15 rain at room temperature.  The cells were allowed to ad- 
here to the protein-coated  surfaces in the presence of the hybridoma super- 
natants for 15-30 min (HT1080) or 2-4 h (lymphocytes) at 37°C. Nonadher- 
ent cells were removed by washing with PBS, and the adherent cells were 
dissolved  in SDS/NaOH  and bound ~lCr counts per minute were quanti- 
tated in a gamma counter. 
Immune Precipitation, Sequential Immune 
Precipitation,  V8 Protease Peptide Mapping, 
and PAGE 
Viable cells  were  surface  labeled  with  1251 as  described  0Vayner  and 
Carter,  1987) followed by extraction with 1% vol/voi Triton X-100 deter- 
The Journal of Cell Biology, Volume 109, 1989  1322 gent  or  0.3%  3-[(3-cholamidopropyl)dimethylammonio]-l-propanesulfo- 
hate (CHAPS) detergent in 50 mM PBS, pH 7.2.  In some cases,  1 mM 
CaCI2  was added to the lysis buffer.  1 mM diisopropyl fluorophosphate, 
I mM PMSF, I mM N-ethylmaleimide, 1 #g/ml leupeptin, and 1 #g/ml soy- 
bean trypsin inhibitor were used as protease inhibitors. Immune precipita- 
tion and sequential immune precipitations were parformed exactly as previ- 
ously described. Peptide analysis followed the basic procedure of  Cleveland 
et al. (1977)  with modifications as described (Wayner and Carter,  1987). 
Polyacrylamide slab gels containing SDS (SDS-PAGE gels) were prepared 
following the basic stacking gel system of Laemmli (1970). 
Preparation of Tryptic Fragments  from Human Plasma 
~bronectin and Synthesis of  CS Peptides 
Human plasma fibronectin was a generous gift from Dr. Horowitz and Dr. 
R.  Schulman (New York Blood Center, New York).  Fibronectin was di- 
gested with TPCK-trypsin for 90 rain at 37°C, and the digest was fraction- 
ated by affinity and ion-exchange chromatography as previously described 
(Garcia-Pardo et al., 1987,  1989).  Two overlapping peptides spanning the 
initial 48 residues of the type III connecting segment (IIICS) region of hu- 
man fibronectin (CS-I and CS-2) were synthesized and coupled to rabbit 
IgG as described (Humphries et al.,  1986,  1987). 
Fluorescence  Anaylsis of  Receptor Expression 
Expression of ECMRs on cells in suspension was analyzed by one- or two- 
color flow cytometry on a dual laser cell sorter (EPICS 750; Coulter Elec- 
tronics, Hialcah,  FL).  Positive fluorescence was determined on a  three- 
decade log scale and fluorescence intensity (log FI) was expressed as mean 
channel number (0-255). Background fluorescence for a nonimmune mouse 
IgG negative control was determined for each cell population and sub- 
tracted. Adherent cells were trypsinized and allowed to recover for 15 min 
at 370C in the presence of serum before use for flow cytometry. For one- 
or two-color fluorescence measurements, 106 cells in suspension were in- 
cubated for 30 min first with protein G-Sepharose-purified goat IgG (20 
#g/ml) and then with first-stage antibodies at 40C for 60 rain, washed in 
HBSS containing 10 mg/ml HBSA and 0.02% sodium azide (HBSS/BSA/ 
SA), and incubated with FITC-conjngated rabbit anti-mouse IgG for 60 min 
at 4"C in HBSS/BSA/SA. They were washed and fixed in cold 2% parafor- 
maldehyde (prepared fresh) in PBS. For two-color fluorescence, the purified 
and biotinylated mAb was added to the FITC-stained and fixed cells to a 
final concentration of 1 #g/ml in HBSS/BSA/SA and incubated at 40C for 
60 rain. Prior fixation with 2 % paraformaldehyde had little effect on expres- 
sion of lymphocyte intagrin receptors. The fixed cells were washed and in- 
cubated  in  0.5  ml  HBSSIBSAISA  containing  phycoerythrin-conjngated 
strepavidin (Bionetics Laboratory Products, Charleston, SC) at 1/50 for 30 
rain at 4°C. Finally, the stained cells were washed and fixed again in 2% 
paraformaldehyde in PBS and held at 4*C in the dark for analysis on the 
flow cytometer. 
Localization of  Receptors in Focal  Adhesions 
Adherent cells were trypsinized, washed in RPMI 1640 supplemented with 
I mg/ml BSA plus 100 t~g/ml soybean trypsin inhibitor, and allowed to ad- 
here to acid-washed and silanized glass cover slips coated with fibronectin, 
laminin, or collagen (20 #g/ml) in the absence of serum for 1-4 h as de- 
scribed (Carter, W. G., and E. A. Wayner,  manuscript in preparation). At 
the end of the incubation, nonadherent cells were removed and adherent 
cells were fixed in 100 mM sodium cacodylate, 100 mM sucrose, 4.5 mM 
CaCI2, 2% formaldehyde for 20 min. They were permeabilized with 0.5% 
Triton X-100 for 5 min, washed, and blocked with 25% goat serum in PBS. 
The permeabilized cells were stained with antibodies to specific receptors 
(60 min at room temperature), washed, incubated with either FITC-con- 
jugated goat anti-mouse or rhodamine-conjugated goat anti-rabbit IgG (45 
min at room temperature), and washed again. The cover slips were inverted 
onto glass slides for fluorescence and interference reflexion microscopy as 
described (Izzard and Lochner, 1976). 
Tissue Staining 
The  distribution of the  integrin  receptors in  tissue  was determined by 
fluorescence microscopy of cryostat sections. Cryostat sections (6 ~tm) were 
prepared from human skin, tonsil, or tumor samples embedded in OCT 
medium after snap freezing in isopentane/liquid nitrogen. All sections were 
fixed in 4 % paraformaldehyde in PBS before incubation in primary antibod- 
ies and secondary fluorescent antibodies as described (Carter and Wayncr, 
1988).  In control experiments, no fluorescence of rhodamine was detected 
using the fluorescein filters or vice versa. 
Results 
Identification of an Alternative Fibronectin Receptor 
Cultured T lymphocytes (Molt 4), K562, RD (rhabdomyo- 
sarcoma), and HTI080 (fibrosarcoma) cells, and freshly de- 
rived  PBL (not shown) adhered  to fibronectin-coated  sur- 
faces (Fig.  1, open bars).  However,  Molt 4  and RD cells 
expressed low or undetectable levels of the prototype fibro- 
nectin  receptor  (integrin  ~5~1)  recognized by monoclonal 
antibody P1D6 (Fig.  1, striped bars).  Consistent with this, 
adhesion of Molt 4 and RD cells to fibronectin could not be 
completely inhibited by P1D6 (Fig.  1, solid bars). Alterna- 
tively,  adhesion of cells to fibronectin that expressed abun- 
dant a5~l (HT1080 and K562) could be effectively inhibited 
by P1D6. Furthermore,  the synthetic peptide RGDS did not 
completely inhibit T lymphocyte adhesion to plasma fibro- 
nectin  (50-70%  for Molt 4 or Jurkat cells vs. 80-90%  for 
fibroblasts and 100% for K562-1 cells). Together, these data 
suggested that some cells,  such as T lymphocytes, express 
fibronectin  adhesion receptors other than c~5~. 
We attempted to identify other putative fibronectin recep- 
tors  by  preparing  mAbs  to  cultured  T  lymphocytes  and 
screening  them for their ability  to specifically  inhibit lym- 
phocyte but not fibroblast adhesion to fibronectin-coated  sur- 
faces. Using this protocol several mAbs (P4C2, P3E3, P4C~) 
were identified that inhibited cultured T lymphocyte but not 
HT1080 cell adhesion to fibronectin (Table I). Immune pre- 
cipitation from Triton X-100 detergent lysates prepared with 
t25I-surface-labeled  PBL  (not shown),  Molt 4  or HT1080 
(Fig. 2) cells showed that the inhibitory mAbs (data shown 
for P3E3) reacted with a single protein present in lympho- 
cyte extracts that migrated at Mr 150,000 (p150) in the pres- 
ence (not shown) or absence (Fig. 2) of reducing agent. Un- 
der these immune precipitation  conditions p150  lacked  an 
apparent ot-/~ subunit structure and did not co-migrate with 
either the ol or/3 subunit of the integrin receptors ot2~l  or 
~3~1 (Fig. 2). The antigen immune precipitated from Triton 
X-100 detergent extracts prepared with chronically  activated 
CD8+ LAK cells or CTL (not shown) contained,  in addition 
to p150,  relatively  large quantifies  of two smaller  proteins 
that migrated at MT 80,000 and 70,000 in the presence (not 
shown) or absence of reducing  agent.  V8 protease  peptide 
mapping  revealed  that p80 and pT0 were proteolytic  frag- 
ments of p150 (not shown). These lower molecular weight 
forms could be immune precipitated  from chronically  acti- 
vated T cells even when detergent extracts were prepared in 
the presence of multiple  protease  inhibitors (legend to Fig. 
2). p80 and p70 were virtually absent from extracts prepared 
with resting  PBL,  cultured  T  (Molt 4,  Jurkat),  or B  cell 
leukemias and RD cells (not shown). 
The biochemical characteristics  of p150 suggested  that it 
might be related to the VLA 4 antigen described by Hemler 
(Hemler et al., 1987a). This was confirmed by sequential im- 
mune precipitation (not shown) with a VLA 4-specific mAb, 
B5-G10. p150 was established as an c~ subunit of the integrin 
super family by its association with E1 when immune pre- 
cipitations  were carried out after CHAPS detergent (0.3%) 
solubilization of t25I-surface-labeled T  lymphocytes in the 
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Figure 1.  Adhesion of T lymphocytes (Molt 4),  K562-1, RD, or 
HT1080  ceils to plasma fibronectin, inhibition with P1D6 mAb, and 
cell surface expression of ~5~1. 5tCr-labeled cells (105 cells/ml) 
were incubated with  P1D6 mAb  (50 #g/ml)  or mouse IgG (50 
#g/ml) for 60 min at 4°C and allowed to attach to fibronectin-coated 
(20/~g/ml) plastic surfaces in the presence of P1D6 (solid bars) or 
mouse IgG (open bars) for 30 min (HTI080 or RD) or 4 h (Molt 
4 or K562) at 37°C. Adhesion to plasma fibronectin (pFN) is ex- 
pressed as 5~Cr bound to the plastic surfaces. Cell surface expres- 
sion of ~5~ was determined by flow cytometry by staining of cells 
in suspension with mAb P1D6. Log P1D6 fluorescence (striped 
bars) is expressed as mean channel number (0-255)  above back- 
ground. 
presence of 1 mM Ca  2+ (Fig. 3). Under these conditions oz4 
was precipitated as a heterodimer with ~1. The identity of B1 
was confirmed by V8 protease peptide mapping (not shown). 
The ot4B1 heterodimer immune precipitated from T lympho- 
cytes with the inhibitory rnAbs (P3E3, P4C2, and P4G9) was 
shown to be distinct from the prototype fibronectin receptor, 
a5f31, immune precipitated with P1D6 by three criteria. (a) 
~__e relative quantities of o~4B1 and oz5B1  present in detergent 
extracts of T lymphocytes were distinct with higher levels of 
a4B1 being present (Fig. 3). This was in agreement with the 
data we obtained using flow cytometry (Fig.  1).  (b) In se- 
quential immune precipitation experiments, mAbs to oz4B1 
Figure 2. Immune precipitation of lymphocyte fibronectin receptor 
from HTI080, Molt 4, or chronically activated CD8 + T (LAK) cell 
detergent extracts, t2SI-labeled Molt 4,  LAK, or HTI080 cells 
were extracted with  1%  Triton X-100 in the presence of 1 mM 
PMSF, 1 mM N-ethylmaleimide, 1/~g/ml leupeptin, and 1 mM di- 
isopropyl fluorophosphate as protease inhibitors. Aliquots of these 
extracts were immune precipitated with mAbs directed to a3/31 
(PIB5), ~2B1 (PIH5) and c~4B1 (P3E3). The immune precipitated 
antigens were run on 7.5 % SDS-PAGE  gels in the absence of  2-mer- 
captoethanol and visualized by autoradiography. The three bands 
immune precipitated with P3E3 from T lymphocytes are indicated 
(arrows). 
Table L Specific Inhibition of  Lymphocyte Adhesion to 
Plasma Fibronectin by mAbs P3E3, P4C2, and P4G9 
Fibronectin  adhesion 
P1D6 
Cells  SP2  (~5B1)  P3E3  P4C2  P4G9 
% of control 
PBL  100  43  38  10  52 
Jurkat  100  22  33  12  48 
Molt 4  100  18  12  8  39 
HT1080  100  5  98  93  104 
Ceils  were labeled  with  StCr and  allowed  to adhere  to plasma  flbronectin- 
coated  (20 t~g/ml) plastic  surfaces (5  x  10  ~ for PBL or l0  s for HT1080 or 
Molt 4 and Jurkat) for 30 rain (HT1080 cells) or 2-4 h (Molt 4 or Jurkat) at 
37°C in the presence of SP2 myeloma or hybridoma culture supernatants dilut- 
ed  1:2  with  fresh  medium.  Results  are  expressed  as a percent  of the  5~Cr 
counts per minute bound to the SP2-positive control.  Data shown are from a 
single experiment.  In general,  the inhibition observed  for the new inhibitory 
mAbs ranged from 50 to 80%, with P4C2 always being the most efficient inhib- 
itor of lymphocyte adhesion to plasma flbronectin. The inhibition obtained for 
PID6 ranged from 10 to 70% for PBL and 50 to 80% for cultured T lympho- 
cyte cell lines. This variability correlated with cell surface expression of ~5B1. 
did not preclear oz5B1 (not shown). (c) The V8 protease pep- 
tide maps derived from the a4 and or5 subunits precipitated 
with mAbs P3E3 and P1D6 were clearly distinguishable (not 
shown).  Furthermore, under the conditions (0.3 % CHAPS 
and 1 mM CaCI2) used to solubilize the conjugate of ot4Bl 
from Jurkat cells (Fig. 3) another protein of  higher molecular 
weight (p180) also reacted with the mAbs or coprecipitated 
with  o~4/31, plS0  was  absent from extracts prepared with 
P1D6 mAb (Fig. 3), nonlymphoid cells or Triton X-100 de- 
tergent extracts prepared in the absence of Ca  2+. The rela- 
tionship of p180 to other integrins is not known. Because or4 
could be immune precipitated without B1 after solubilization 
of T cells with Triton X-100 in the absence of Ca  2÷ this re- 
vealed that the inhibitory mAbs recognized epitopes present 
on the c~4 subunit (Fig. 2). 
Distribution of ~4{31 and ~5131 in 
Cultured Cells and Tissues 
As has been previously reported (Hemler et al., 1987a), a4/31 
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as integrin  ot4/31. ~25I-surface-labeled Jurkat cells were extracted 
with 0.3%  CHAPS in the presence of 1 mM CaC2,  1 mM diiso- 
propyl-fluorophosphate,  1 mM PMSF,  1 mM N-ethylmaleimide, 
1 #g/ml leupeptin,  and 2/zg/ml soybean trypsin inhibitor. Aliquots 
of the extracts were then immune precipitated with myeloma (SP2) 
culture supernatant or with mAbs P3E3, P4C2, P4G9, or with P1D6 
(anti-tx5/~l). The immune precipitates were run on 8% SDS-PAGE 
gels in the absence of reducing agent and visualized by autoradiog- 
raphy. (le~) Molecular weight markers. The ct5 and/~1 subunits are 
indicated as are the bands present in immune precipitates prepared 
with P3E3,  P4C2,  and P4G9  (arrows). 
was widely distributed on nucleated hematopoietic cells (Ta- 
ble II). Two-color flow cytometry revealed that all lympho- 
cyte subpopulations derived from spleen, tonsil, and periph- 
eral blood expressed abundant t~4/~l. In addition, peripheral 
blood monocytes, freshly derived acute lymphocytic  (T or B) 
leukemias, all LGL and myelogenous leukemias, and cul- 
tured T and B lymphocyte cell lines we examined expressed 
abundant ot4/~l (Table 1I). Normal human blood platelets and 
granulocytes were negative for ~4/31. In contrast, the only 
hematopoietic cell populations that expressed ot5/ffl were ac- 
tivated T cells, platelets, monocytes, and granulocytes; acute 
lymphocytic (T or B) and myelogenous leukemias; and cul- 
tured K562, HL-60, and U93"/cells. Some cultured T (Molt 
4 or Jurkat) and B (ST-l) cell lines expressed low levels of 
ot5/31 as detected by P1D6 mAb. In some normal individuals, 
a subpopulation of PBL were positive for PID6 fluorescence 
detected by flow cytometry. We are investigating the nature 
of this subpopulation of PBL that expresses ot5/31. YT cells, 
a  CD3-  T  cell  lymphoma, were  completely negative for 
P1D6 by flow cytometry. These results show that the major 
fibronectin receptor constitutively expressed by T lympho- 
cytes is ot4/~l and as we have previously reported (Wayner 
Table IL Distribution of  the Fibronectin Receptors 
tz4~l and ~5~1 on Human Cells 
Relative 
fluorescence intensity 
Cells  ot4/~l (P4G9)  ot5/~l  (P1D6) 
Hematopoietic cells* 
PBL  +  +  +  +/-  or  - 
LGL (CD3-,  CDI6+)  +++  +/-  or  - 
Monocytes (CD16+)  + +  + + 
Granulocytes  -  + 
Platelets  -  + 
Spleen  + +  +  + 
Tonsil  + +  +  + 
ALL(TorB)  +++  ++ 
LGL leukemia (CD3+,  CDI6+)  + +  +  +/- 
AML  +++  ++ 
BLCL  +  +  + 
Molt 4  (CD3 +,  CD4 +)  +  +  +  + 
Jurkat (CD3 +,  CD4+)  + +  +  + + 
YT (CD3-)  +  +  - 
PHA blasts (CD4+)  + + +  +  + + 
CTL (CD3+,  CD8+)  ++++  +++ 
LAK (CD3+, CD8+)  ++++  +++ 
HL-60  + +  + 
U937  +  +  + 
K562-1  -  + + 
Fibroblasts~ 
HFF (p5)  +  + 
HT1080  +  + + 
RD  +  +  + 
VA13  +  +  + 
Epithelial cells 
OC-I§  -  - 
OVCAR-411  -  - 
T47D  -  - 
QG56  -  + 
HUVEs (pl)¶  -  + + 
Relative fluorescence intensity was determined as described in Materials and 
Methods by flow cytometry.  Each plus corresponds to 50 channels on a three- 
decade log scale from 0 to 255.  -,  no detectable fluorescence above back- 
ground.  +/-,  a positive shift in fluorescence above background,  mAbs used 
in all flow cytometry experiments were P4CO and PID6 (10 t~g/ml). Fc recep- 
tors were blocked by preincubation  with Protein  G-Sepharose-purified  goat 
IgG (20 #g/ml). Protein G-Sepharose-purified  mouse IgG was used a negative 
control for background staining and detection of possible residual Fc receptor 
interaction.  In general,  data obtained with Fc receptor-  (CDI6) positive cell 
populations has to be interpreted with caution.  In addition,  the phenotype of 
cells in culture can vary from experiment to experiment.  The reason for this 
is unknown. The data presented here are representative  of the phenotype ex- 
pressed  most often by cultured cell lines. 
* PBL,  tonsil  or splenic  lymphocytes  were prepared  by standard  protocols 
without enzymatic degradation and stained in suspension for flow cytometry. 
Peripheral  blood subpopulations were distinguished either by two-color  flow 
cytometry analysis or by the use of forward light and high angle (90*) scatter. 
PBL,  resting  peripheral  blood  lymphocytes  from normal  individuals.  CTL, 
CDS+  long-term,  antigen-specific  eytotoxic T  lymphocyte  cell  line.  LAK, 
CD8 +  non-antigen-dependent  lymphokine-activated killer cells. 
:~ Fibroblasts  were trypsinized  and  analyzed  for cell  surface  expression  of 
receptors in suspension. Trypsin was inactivated with soybean trypsin inhibitor 
and the cells were allowed to recover at 37"C for 10 rain before use. HFF, hu- 
man neonatal foreskin fibroblasts,  passage 5 (p5). 
§ OC-I cells were derived from the aseites fluid of a woman with ovarian car- 
cinoma.  They were fresh frozen and thawed just before staining.  These cells 
are nonadherent  in culture. 
U  OVCAR-4  cells  are  a well-established  adherent  cell  line derived  from an 
ovarian  carcinoma. 
¶ HUVEs,  large vessel endothelial cells obtained from Cell Systems (Seattle, 
WA) and were used at passage  1. They were derived  from human umbilical 
cords and grown to confluence in sentm-free  media (Cell Systems). They ex- 
hibited typical characteristics  of HUVEs. 
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and c~5/31 in focal adhesions on 
flbmnectin-coated  surfaces.  RD 
cells were trypsinized and allowed 
to adhere to silanized and fibro- 
nectin-coated  (20  #g/ml)  glass 
cover slips in the absence of se- 
rum for 1 h at 37"C. At the end of 
this time, the cells were prepared 
for localization of receptors in fo- 
cal adhesions as described (Ma- 
terials and Methods). (.4 and C) 
Focal  adhesions  (arrows) visu- 
alized  by  interference  reflexion 
microscopy when  RD  cells  are 
adhered to fibronectin. (B) Reor- 
ganization of the prototype fibro- 
nectin receptor ot5B1 stained with 
antibody AB33 to the focal adhe- 
sions (arrows). (D) Reorganiza- 
tion of oMB1 stained with P4G9 
(FITC) also to the focal adhesions 
when RD cells are adhered to fi- 
brotw,  ctin (arrows). A and B are 
the same fieM  and C and D are the 
same field. 
et al.,  1988), expression of c~5/~1 in T  lymphocytes is re- 
stricted to leukemic or activated cultured cells. Interestingly, 
most  fibroblast  cell  lines  expressed  low  levels  of ot4/~l, 
whereas large-vessel endothelial cells and cultured epithelial 
cells were negative for ot4/~l by flow cytometry. 
In tissue, ot4/~l was present in adult spleen, lymph node, 
and tonsil and essentially absent from all other tissues we ex- 
mined (not shown). In addition, the relative quantities of  the 
fibronectin adhesion receptors expressed by cells in specific 
tissue domains varied dramatically. For example, PBL and 
lymphocytes in tonsil cortex and germinal center areas ex- 
pressed large quantifies of ot4B1 but virtually no ot5fll, o~4/31 
was also found in epithelial regions in adult lymphatic tissue, 
but whether this was the result of lymphocyte infiltration of 
these areas or expression of ot4fll  by lymphatic epithelial 
cells was unclear. 
c~4fl  l Localizes in Fibronectin-dependent 
Focal Adhesions 
There is a  specific reorganization of cell surface adhesion 
receptors to the focal adhesions when cells are grown on the 
appropriate ligands  in the absence of serum (reviewed by 
Burridge et al., 1988). As some fibroblasts express c~4B1, we 
investigated whether this receptor would distribute into focal 
adhesions when fibronectin was used as the adhesion sub- 
strate. As can be seen in Fig. 4, A and C, the primary focal 
contact sites or focal adhesions could be visualized by inter- 
ference reflexion microscopy (Izzard and  Lochner,  1976) 
when RD cells were grown on fibronectin. As we and others 
have reported (Roman et al., 1989), in the absence of serum, 
a5/31 was concentrated at the focal adhesions when RD cells 
were grown on fibronectin (Fig. 4 B, arrows) but not laminin- 
coated surfaces (not shown). Likewise, staining with mAb 
P4CO (Fig. 4 D, arrows) revealed that t~4B1 was also concen- 
trated in focal adhesions when cells were grown on fibro- 
nectin- but not laminin-coated surfaces (not shown). These 
results demonstrate a specific interaction of t~4B1 with fibro- 
nectin present in focal adhesions, the primary adhesion struc- 
ture of cultured cells. 
The presence of both receptors in focal contacts suggested 
the possibility that ot4/~l and otSBl bind to distinct adhesion 
sequences  in  fibronectin.  Evidence for this  was  obtained 
when P4C2 and P1D6 were used simultaneously to inhibit 
cell adhesion to intact plasma fibronectin. P1D6 and P4C2 
when used together completely inhibited adhesion of T lym- 
phocytes and partially inhibited adhesion of RD cells to in- 
tact plasma  fibronectin (Table III).  Interestingly, unlike T 
lymphocytes, neither P1D6 nor P4C2 alone were good inhib- 
itors of RD cell adhesion to intact plasma fibronectin. RD 
cell adhesion to fibronectin could be efficiently inhibited by 
P1D6 and P4C2 only when used together. 
ot4B1 Functions as the Receptor  for an 
RGD-independent Alternative Attachment Site 
in l~bronectin 
The preceding results (Tables I and HI, Figs. 1 and 4) clearly 
indicated that attachment of some cells to plasma fibronectin 
was  mediated by two  independent cell  surface  receptors, 
c~4B1 and ot5B1. It has been well documented that the ligand 
for ot5B1 in fibronectin is the 80-kD cell-binding domain that 
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Lymphocyte and RD Cell Adhesion to Fibronectin 
Cells  Antibody  Specificity  Adhesion 
RD 
Jurkat 
% of control 5: SD 
I  GG  -  100 
P1D6  et5/~l  81  +  11 
P4C2  ~4~ 1  99 +  7 
PID6  +  P4C2  36 -t- 8 
IGG  -  100 
PID6  a5/~l  26 +  9 
P4C2  o~4/~1  38 +  14 
P1D6 +  P4C2  O 
Cells were labeled with 5~Cr and incubated in the presence of the indicated 
mAbs (50 ~tg/ml)  or purified mouse  IgG (50 ttg/ml) for 1 h at 4"C. They  were 
then applied to plasma  fibroneetin-coated  (20 ttg/ml) surfaces in RPM11640/I 
mg/ml HBSA  and incubated  at 37"C for 30 rain (RD cells) or 2 h (Jurkat). At 
the end of this incubation, nonadherent  cells were  washed  off with warm  PBS 
and the bound counts per minute were solubilized and quantitated in a gamma 
counter. Results from  several  experiments  were pooled and are expressed  as 
mean percent (relative to control) + SD. 
contains the RGD sequence (Pierschbacher and Ruoslahti, 
1984; Pytela et al.,  1985). To determine the region of fibro- 
nectin that interacts with o~4/31, we examined the adhesion of 
cultured T  lymphocytes to various proteolytic fragments of 
plasma fibronectin (see Fig. 5, A and B), as well as the effect 
of mAbs P1D6 and P4C2 on lymphocyte adhesion to these 
fragments. As shown in Fig. 6, Jurkat, YT, and Molt 4 (not 
shown) cells attach to a 38-kD fragment containing the Hep- 
arin (Hep) II domain much more efficiently than to an RGD- 
containing fragment (80 kD). Jurkat and Molt 4 cells also at- 
tach in a dose-dependent manner to another Hep II domain- 
containing  fragment of 58 kD (not shown).  Maximum cell 
attachment to the 58-kD fragment, however,  reached only 
30%  of that achieved by the  38-kD  fibronectin fragment. 
This suggests that the 38-kD fragment contains a high-affin- 
ity attachment site for T lymphocytes. T lymphocytes did not 
adhere to the NH2-terminal 29-kD fragment containing the 
Hep I domain of plasma fibronectin (not shown). In general, 
freshly derived PBL showed a similar pattern of attachment 
as Jurkat or Molt 4  cells and the ability of freshly derived 
PBL to bind to the 80-kD fragment correlated with expres- 
sion of ot5/31 (not shown).  Other hematopoietic cell lines, 
such as K562 cells (Fig. 6) exhibited a clear preference for 
the 80-kD fragment of plasma fibronectin, whereas RD cells 
expressed promiscuous adhesion to all the fragments of plas- 
ma fibronectin tested, except the NH2-terminal 29-kD frag- 
ment  (not  shown).  RGDS  (1  mg/ml)  partially  inhibited 
(50%) Jurkat cell  adhesion to intact fibronectin and com- 
pletely (100%) inhibited their adhesion to the 80-kD frag- 
ment. Jurkat cell adhesion to the 38-kD fragment was un- 
affected by RGDS (up to  1 mg/ml). 
As we have previously shown (Table I and Fig.  1), mAbs 
to a4/~l and ,5/31 partially inhibited T lymphocyte adhesion 
to intact plasma fibronectin (Fig. 7, top). As expected, P1D6 
completely inhibited adhesion of T  cells to the 80-kD frag- 
ment, which contains the RGD adhesion sequence (Fig. 7, 
middle). P1D6 did not inhibit T lymphocyte adhesion to the 
38- (Fig. 7, bottom) or 58-kD (not shown) fragments. In con- 
trast, P4C2 completely inhibited T  lymphocyte adhesion to 
the 38-kD fragment and had no effect on adhesion to the 80- 
kD fragment (Fig. 7). Furthermore, adhesion of T lympho- 
cytes to the 58-kD fragment which also contains Hep II could 
be inhibited by P4C2. In every case other T lymphocyte cell 
lines  which  express both ot4/31 and  ot5/31 (such  as Jurkat 
cells) behave exactly as Molt 4 cells (Fig. 7). As seen in Table 
II, K562 cells express only t~5/31. Adhesion of K562 cells to 
the 38- (Fig. 6) and 58-kD fragments (not shown) was greatly 
Figure 5. (,4) Domain structure of 
human plasma fibronectin (pFN) 
showing the origin of  the fragments 
used in this study. (B) SDS-PAGE 
gel  analysis  (10% acrylamide) 
demonstrating  the  purity  of the 
fragments.  The 80-kD  fragment 
had the NH2-terminal amino acid 
sequence SDOVPSPROLQF, and 
therefore begins at position 874 of 
the  fibronectin  molecule  (Koru- 
blihtt et al., 1985). This fragment 
contains the cell binding domain 
(Cell) and the RGDS sequence of 
fibronectin (*). the 58- and 38-kD 
fragments had the NH2-terminal 
amino acid  sequence  TAGPDQ- 
TEMTIEGLQ.  Both  fragments 
contain the COOH-terminal  hep- 
arin binding domain (Hep II) and result from a different cleavage of the two fibronectin chains by trypsin. The 38-kD fragment comprises 
the first 67 amino acid residues of the alternatively spliced connecting segment of fibronectin (IIICS) (Garcia-Pardo et al.,  1987) and it 
is therefore derived from the A chain.  The 38-kD fragment does not contain the REDV adhesion site recognized by BI6-FI0 melanoma 
cells (Humphries  et al.,  1986, 1987). The 58-kD fragment is derived from the B chain of fibronectin and lacks the mCS region (Gar- 
cia-Pardo, unpublished). The 58-kD fragment also contains the COOH-terminal fibrin binding domain of fibronectin (Fib II), and is similar 
to previously reported fragments from this region of  plasma fibroncctin (Click and Balian, 1985; Rogers et al., 1985). The bands are visual- 
ized by staining with Coomassie blue. 
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l~gure 6. Adhesion of hema- 
topoietic cells to plasma fibro- 
neetin and the purified 38- and 
80-kD  tryptic  fragments  of 
plasma  fibronectin.  5!Cr-la- 
beled I(562 (erythroleukemia), 
Jurkat (CD3+ T lymphocyte), 
and  YT (CD3-  T  lympho- 
cyte) cells (10S/well) were al- 
lowed to adhere to plastic sur- 
faces  that  had  been  coated 
with intact plasma fibronectin 
(pFN) or the purified 80- and 
38-kD  tryptic  fragments  at 
the  indicated  concentrations 
(y-axis) for 2 h at 37"C. At the 
end of this time, nonadherent 
cells were washed off and the 
bound cells were solubilized 
results are expressed as bound 
.  8OkO 
<3  ,,~ 
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Figure 7.  Effect of the mAbs 
PtD6 and 1)4(22 to the integrin 
receptors (~5#1 and ~4/~1, re- 
speetively, on adhesion of T 
lymphocytes to intact plasma 
fibronectin (pFN) or the pu- 
rified 80- and 38-kD tryptic 
fragments. 5'Cr-labeled Molt 
4  cells  were  incubated  with 
purified 1)11:)6  or P4C2 mAbs 
(50 t~g/ml) or purified mouse 
IgG (50 t~g/ml) for 1 h at 4"C. 
They were then allowed to ad- 
here to plastic  surfaces  that 
had  been  coated  with  intact 
plasma fibronectin, or the 80- 
and  38-kD tryptic fragments 
at the indicated concentrations 
(y-axis) for 1 h. At the end of 
this  time,  the  nonadherent 
cells were washed off and the adherent cells were solubilized and 
bound  5~Cr counts  per  minute  were  quantitated  in  a  gamma 
counter. The results are expressed as bound counts per minute. 
reduced when compared to their adhesion to the 80-kD frag- 
ment  (Fig.  6).  Adhesion  of these  cells  to  intact  plasma 
fibronectin (Fig. 1) or the 80-kD fragment (not shown) could 
be completely inhibited by P1D6.  On the other hand,  YT 
cells, which do not express ot5B1 (Table II), adhere poorly 
to intact plasma fibronectin and the 80-kD fragment (Fig. 6). 
These cells require two to three times longer to adhere to 
plasma fibronectin-coated surfaces than Jurkat or Molt 4 
cells. YT cells, however, adhere efficiently and in a dose- 
dependent manner to the 38-kD fragment (Fig. 6) and adhe- 
sion of  these cells to the 38-kD fragment could be completely 
inhibited by P4C2 (not shown). These data indicate a direct 
correlation between expression of (x4/~l and the ability to at- 
tach to fragments of plasma fibronectin containing the Hep 
II  and  IIICS  regions.  Furthermore,  these  data  show  un- 
equivocally that ot4/~l functions as the receptor for this alter- 
native cell adhesion domain. 
~4/31 Is the T Lymphocyte Receptor  for CS-I 
The IIICS region present on the A chain of plasma fibronec- 
tin (Fig. 5) contains at least two sites responsible for mediat- 
ing cell adhesion to fibronectin (Humphries et al.,  1986, 
1987, 1988). Using a series of  overlapping synthetic peptides 
spanning the entire IIICS region (CS peptides), Humphries 
and co-workers showed that the CS-1  (NH2-terminal) and 
CS-5  (COOH-terminal)  peptides  contained  adhesion  se- 
quences recognized by mouse melanoma cells (Humphries 
et al., 1986, 1987). We have shown here that the 38-kD frag- 
ment contains a high-affinity adhesion site recognized by T 
lymphocytes and that o~4#1 is the receptor that mediates T 
lymphocyte adhesion to 38 kD. This fragment does not con- 
tain the CS-5 site but it does contain the entire CS-1 region 
(Garcia-Pardo et at.,  1987), which was defined as a high- 
affinity adhesion site for melanoma cells (Humphries et al., 
1987). Therefore, it was of interest to determine ifT lympho- 
cytes would recognize and bind to CS-1 and if a4/~l  was the 
receptor involved in this interaction. 
T lymphocytes (Jurkat or Molt 4 cells) recognize and at- 
tach to CS-1 (rabbit IgG conjugate) -coated plastic surfaces 
(Table IV). Jurkat cells do not attach to CS-2 (rabbit IgG con- 
jugate) -coated surfaces or to plastic surfaces coated with 
rabbit IgG alone (not Shown).  Furthermore, mAbs to oL4/~l 
(P4C2) completely inhibited T lymphocyte adhesion to CS-1, 
whereas antibodies to (x5~l  (P1D6) had absolutely no effect 
(Table IV). As we have previously shown, antibodies to ~4fll 
completely and specifically inhibited T lymphocyte adhesion 
to the 38-kD  fragment (Table IV),  whereas antibodies to 
~5/~1 specifically inhibited adhesion to the RGD containing 
80-kD fragment. 
Discussion 
In this study, we have described a new fibronectin receptor, 
identical to the integrin receptor a4/~l (Hemler et al., 1987a), 
preferentially expressed by nucleated hematopoietic cells. 
Identification of ~4~1 as a specific fibronectin receptor was 
based on (a) inhibition of cell adhesion to fibronectin by 
mAbs P4C2, P3E3, and P4G9, and (b) specific reorganiza- 
tion and concentration of a4~l  into fibronectin-dependent 
focal adhesions. These findings suggest that c~4B1 and ~5fll 
function together as primary mediators of cell adhesion to 
fibronectin. 
rnAbs to either ~5~1 or ot4~l partially inhibited T lympho- 
cyte adhesion to intact fibronectin. However, inhibition of T 
lymphocyte or RD  cell adhesion to  fibronectin was  most 
efficient when the inhibitory antibodies to o~4/~1 and o~5/31 
were used together. This suggested that these receptors rec- 
ognized independent sites on intact fibronectin. It has been 
well documented that the ligand for c~5fll is the cell binding 
domain containing the RGD sequence (Pytela et al.,  1985). 
Analysis of the region of fibronectin recognized by a4/31 was 
accomplished by examining the ability of the functionally 
defined mAbs  to  inhibit  lymphocyte adhesion to purified 
tryptic fragments of plasma fibronectin. Although T  lym- 
phocytes attached to the 80-kD cell binding domain (Fig. 5 
A)  they demonstrated a  clear preference for a  non-RGD- 
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to CS-1 Peptide with mAbs to ce4B1 
Antibody 
Ligand  IgG  P4C2  P 1  I)6 
~lCr cpm bound to the adhesion surface 4- SD 
80 kD  8,580  +  214  7,154  +  398  202  5:105 
38  kD  22,680  5:1,014  114  5:78  24,917  5:352 
CS-1  44,339  +  513  841  +  555  42,897  5:728 
CS-2  2,576  +  214  535  5:258  435  5:168 
Jurkat  cells were labeled with 5~Cr and incubated in the presence of the indi- 
cated mAbs (50 t~g/ml) or purified mouse IgG (50 t~g/mi) for 1 h at 4"C. They 
were then applied to plastic surfaces coated with the 80- and 38-kD tryptic plas- 
ma fibronectin  fragments  (10/~g/ml)  or the CS-1 and CS-2 rabbit  IgG con- 
jugates (1:100). After a 2-h incubation at 370C, nonadherent cells were washed 
off with warm PBS and the bound counts per minute were solubilized and quan- 
titated in a gamma counter. Results from several experiments were pooled and 
are expressed as 5~Cr counts per minute bound to the adhesion surface  -1- SD. 
containing region located on a 38-kD tryptic fragment de- 
rived from the A (or heavy) chain of plasma fibronectin. In 
the present study we have shown that T  lymphocytes also 
recognize and bind to another Hep II-containing 58-kD frag- 
ment.  However, the high-affinity lymphocyte binding site 
was located on the 38-kD fragment. On a molar basis, the 
38-kD fragment was three times more efficient than the 58- 
kD fragment in mediating T lymphocyte  adhesion. As shown 
in Fig. 5 A, the 38- and 58-kD fragments were derived from 
the A and B chains of plasma fibronectin, respectively. They 
therefore differ in the presence or absence of HICS (Korn- 
blihtt et al., 1985; Garcia-Pardo et al., 1987). Thus, it is pos- 
sible that the 38- and 58-kD fragments used here share a 
common low affinity T lymphocyte binding site, located in 
the Hep II domain, and that additional high-affinity T lym- 
phocyte adhesion sites are present in the IIICS region unique 
to the 38-kD fragment. We show here that T lymphocytes 
specifically recognize and bind to  CS-1,  which has been 
defined as a high-affinity adhesion site for B16 melanoma 
cells and avian neural crest cells (Humphries et al.,  1987, 
1988;  Dufour  et  al.,  1988).  Furthermore,  as  we  have 
reported (Garcia-Pardo, A., and O. C. Ferreira, manuscript 
submitted for publication) soluble CS-1 (500 t~g/ml), how- 
ever, did not completely inhibit T lymphocyte  adhesion to the 
38-kD fragment. This supports the notion that T lympho- 
cytes may use other sites (possibly in Hep II) during their 
adhesion to fibronectin. 
T  lymphocyte adhesion to the 38- and 58-kD fragments 
could be completely inhibited by functionally defined mAbs 
to a4E1. Furthermore, T lymphocyte adhesion to CS-1- (IgG 
conjugate) coated surfaces could also be completely inhib- 
ited by P4C2, P3E3, or P4G9. These data show clearly that 
o~4E1 is the T  lymphocyte receptor for CS-1. In contrast, 
these antibodies failed to inhibit adhesion of T cells to the 
80-kD fragment containing the prototype adhesion sequence 
arg-gly-asp (RGD). Adhesion of T cells to the 80-kD frag- 
ment could be  completely inhibited by an  mAb to ot5/31 
(P1D6) or by RGDS. P1D6 and RGDS failed to inhibit T lym- 
phocyte adhesion to the 38- and 58-kD fragments or to CS-1. 
Together, these data show that ~x4E1 functions as the receptor 
for the carboxy-terminal adhesion domain of plasma fibro- 
nectin, ot4E1 is, therefore, clearly a new and RGD indepen- 
dent fibronectin receptor for alternative adhesion sequences 
in IIICS (CS-1) and possibly Hep II. 
Recently, Bernardi et al.  (1987)  and Liao et al.  (198% 
1989) reported that some B lymphocyte cell lines bind to a 
region of plasma fibronectin located within the carboxy- 
terminal Hep II domain.  Liao et al.  (1987)  identified an 
integrin-like receptor on B cells.  However, it is not clear 
whether the protein they described was ~x4E1 or ot5E1. Ber- 
nardi et al. (1987)  also identified fibronectin receptors ex- 
pressed by B lymphocytes. Interestingly, in this study, B cells 
that attached to fragments containing Hep II expressed a 
receptor similar to ot4E1, whereas cells that attached to the 
RGD-containing cell adhesion domain expressed a receptor 
similar to o~5E1. Together,  the results of these previous re- 
ports and the present findings provide clear evidence in sup- 
port of (a) the existence of an alternative adhesion domain 
present in the carboxy-terminal region of plasma fibronectin 
and (b) a  role for ot4131 as the receptor for this alternative 
adhesion site. It will be interesting to determine the precise 
amino acid sequences responsible for ot4131 interaction with 
fibronectin. As neither of the 38- or 58-kD fragments nor 
CS-1 contains an RGD sequence (Kornblihtt et al.,  1985; 
Garcia-Pardo et al.,  1987; Humphries et al.,  1986, 1987), 
it is clear that characterization of the ligand for a4E1  will 
identify a new amino acid sequence important for cell adhe- 
sion to fibronectin. Because the 38-kD fragment does not 
contain CS-5 (Garcia-Pardo et al., 1987), the minimal amino 
acid sequence responsible for T lymphocyte adhesion to 38 
kD and therefore the ligand for u4/31 in these cells is not arg- 
glu-asp-val  or REDV (Humphries et al.,  1986). 
Like ot2E1, the o~4 subunit is weakly associated with the 
B1 subunit. The data presented here (Fig. 2) and our previous 
findings (Wayner and Carter,  1987; Wayner et al.,  1988) 
show that the functionally defined mAbs to ot2/31 and ot4E1 
selectively interact with epitopes present on the a  subunits, 
based on immune precipitation of ol2 or c~4 without E1 after 
subunit dissociation. These results suggest that the unique ot 
subunit is  responsible  for determining the  ligand-binding 
specificity of each o~-E complex. This concept is now further 
supported by the observations presented here that or5 and or4, 
which are both complexed with El, mediate adhesion to dis- 
tinct sites on fibronectin. This is not to suggest that the B sub- 
unit is not important in binding, but that the specificity of 
receptor-ligand interactions is determined by ot or a unique 
oL-B complex. 
It is interesting that although LAK cells expressed abun- 
dant cell surface ot4/31, it did not appear to be a functional 
receptor; P1D6 completely inhibited LAK cell adhesion to 
fibronectin (not shown). The reason for this could be that 
LAK cells express a degraded form of a4 (see Fig. 2). In ad- 
dition, because they are activated, LAK cells over express 
cx5E1 when compared with resting peripheral blood or leu- 
kemic T cells (Table II). In other cells that express larger 
quantities of o~5/31 relative to ot4E1 (K562-1  and HT1080) 
adhesion to the 80-kD RGD-containing domain via ot5E1 is 
dominant (see K562-1 cells, Fig. 6). This implies that regula- 
tion of receptor expression determines the ability of a cell to 
recognize and bind to different sites on fibronectin. Further- 
more, it is also possible that coexpression of the two recep- 
tors for fibronectin could increase the avidity of cell binding, 
for example Jurkat and RD cells, which express relatively 
promiscuous adhesion to fibronectin when compared with 
YT ceils, which express only a4~l. 
The regulation of cell adhesion to fibronectin is potentially 
Wayner et al. Lymphocyte Fibronectin  Receptors  1329 complex even under the simplest possible conditions, which 
assume that a5/~1  and ot4B1 function independently of each 
other and do not overlap during  interaction  with  the two 
binding sites on fibronectin. Variation from this simple state 
provides opportunities for exquisitely sensitive regulation of 
cell adhesion. At the least complex level, this regulation can 
be roughly eatagorized as (a) processes that control the syn- 
thesis and/or exposure of the binding sites on the ligand and 
(b) regulation of functional expression of the receptors.  Ex- 
amples of regulation at both levels are currently available and 
include, the observation that lymphokines and specific anti- 
gen induce o~5/~1 expression on T lymphoeytes followed by 
increased cell adhesion to fibroneetin (Wayner et al.,  1988, 
and unpublished). In addition, the control of mRNA splicing 
in the RICS region of fibroneetin (Kornblihtt et al.,  1985) 
during wound healing or inflammation may dictate the speci- 
fiery  of reeeptor-ligand  binding  in  resting  or activated  T 
cells.  Variations from the simple state are intriguing but re- 
quire additional experimentation to even begin to identify the 
multitude of potential mechanisms. 
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Note added in proof. We have identified a minimal peptide derived from 
the carboxy terminal portion of CS- 1,  LHGPEILDVPST,  which inhibits 
T  lymphocyte adhesion to plasma fibronectin, 38 kD, and CS-I. 
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